Hebrew University drug trials show 50 percent cure rate in lab mice
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.
As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)’s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.
Leukemia produce a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.
To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during “targeted therapy” treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.
However, the new drug developed by Ben-Neriah and his team functions like a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the leukemia cells to activate other proteins that can evade the therapy. Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.
Additionally promising, is the new drug’s ability to eradicate leukemia stem cells. This has long been the big challenge in cancer therapy and one of the main reasons that scientists have been unable to cure acute leukemia.
“We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice’s’ leukemia signs disappeared overnight,” shared professor Ben-Neriah.
BioTheryX recently bought the rights to this promising drug from HU’s technology transfer company Yissum. Together with Ben-Neriah’s research team, they are now applying for FDA approval for phase I clinical studies.
The Latest on: Acute myeloid leukemia
via Google News
The Latest on: Acute myeloid leukemia
- Acute Myeloid Leukemia Treatment Industry Global Market Size, Growth, Share, Supply, Demand, Segments and Forecast 2019-2025 on January 3, 2019 at 5:27 am
(MENAFN - iCrowdNewsWire) Global Acute Myeloid Leukemia Treatment Market 2019 Industry Research Report is a professional and in-depth study on the current state of the Global Acute Myeloid ... […]
- New Potential Treatment for Leukemia Discovered on December 30, 2018 at 5:19 am
‘A compound being developed to treat a form of eye disease also kills leukemia cells.’ Acute myeloid leukaemia (AML) is a form of blood cancer that affects people of all ages, often requiring months o... […]
- Chemotherapy for Solid Tumors Associated With Increased Risk of AML, MDS on December 28, 2018 at 7:32 am
Patients who are treated with chemotherapy for their solid tumors have an increased risk of therapy-related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML) despite advances in chemother... […]
- Pediatric leukemia ‘super drug’ may be within reach on December 28, 2018 at 5:44 am
There are several types of leukemia. The new research focuses on the two most common found in infants through teenagers: acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). For the past ... […]
- Pediatric Leukemia Super Drug Could Become Reality on December 27, 2018 at 11:37 am
There are several types of leukemia. This research focused on the two most common found in infants through teenagers: acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). For the past 25 ... […]
- Mother with leukemia in need of stem cell transplant on December 26, 2018 at 5:06 pm
The young mother was diagnosed in October with acute myeloid leukemia, or AML, an aggressive blood cancer that has left her tired and unable to work. Now, she is using her story to urge others to join ... […]
- Elevated MDS/AML Risk Post-Chemotherapy for 22 of 23 Solid Cancers on December 26, 2018 at 1:33 pm
The goal is to determine the association of treatment-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML) with chemotherapy in patients previously treated for solid cancer tumors. In th... […]
- Syracuse man battling leukemia gets gift of life from niece, comes home for Christmas on December 24, 2018 at 11:55 am
He reported to the hospital several hours after he was told to do so, and learned the next day he had acute myeloid leukemia. "I was like a deer in headlights - I had no idea what was coming,'' the Sy... […]
- Dr. Andreeff Discusses Promise of Venetoclax in AML on December 21, 2018 at 10:59 am
Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of venetoclax (Venclexta) in the treatment of patients with acute myeloid ... […]
- Minnesota Moment: Rochester 15-month-old battling leukemia is a billboard star on December 20, 2018 at 7:24 pm
A 15-month-old girl is appearing on billboards all over Rochester as she battles against acute myeloid leukemia. Gabby Brown went through her second round of chemotherapy in October. And the ... […]
via Bing News